MDxHealth SANASDAQ: MDXH

Mdxhealth to Release Second Quarter 2026 Financial Results on August 13

· Issued by MDxHealth SA via GlobeNewswire

Summary by 6ix AI

Mdxhealth SA, a diagnostics company whose tests help doctors diagnose prostate cancer and other urologic diseases, will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026.

Key details

  • Mdxhealth will host a conference call and webcast with live questions and answers on August 13, 2026, at 4:30pm ET / 22:30 CET.
  • Dial-in numbers are 1-833-309-3473 (United States), 0800 72 519 (Belgium) and 0808 101 1183 (United Kingdom), with conference ID MDX2Q26.
  • A replay of the webcast will be available on the company's website after the live call ends.

6ix AI wrote this summary from the release below and checked it against the release.

Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET

IRVINE, California – July 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the second quarter ended June 30, 2026, after market close on Thursday, August 13, 2026.

Title:

Mdxhealth Presents Second Quarter 2026 Financial Results and
Corporate Update Conference Call and Webcast

Date:

August 13, 2026

Time:

4:30pm ET/ 22:30 CET

Conference Call Dial-in Details:

United States: 1-833-309-3473
Belgium: 0800 72 519
United Kingdom: 0808 101 1183

Conference ID:

MDX2Q26

Webcast:

The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company's website.

About Mdxhealth

Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

[email protected]

LifeSci Advisors (IR & PR)
John Fraunces, Managing Director
Tel: +1 917 355 2395
[email protected]

MDxHealth SA on 6ix

Story so far

Earlier from MDxHealth

Later from MDxHealth

All MDxHealth news releases